Late occurrence of hepatic veno-occlusive disease following gemtuzumab ozogamicin: successful treatment with defibrotide

Br J Haematol. 2003 Nov;123(4):752-3. doi: 10.1046/j.1365-2141.2003.04667.x.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Acute Disease
  • Aged
  • Aminoglycosides / adverse effects*
  • Aminoglycosides / therapeutic use
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Female
  • Gemtuzumab
  • Hepatic Veno-Occlusive Disease / drug therapy
  • Hepatic Veno-Occlusive Disease / etiology*
  • Humans
  • Leukemia, Myeloid / drug therapy
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Polydeoxyribonucleotides / therapeutic use*
  • Time Factors

Substances

  • Aminoglycosides
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Platelet Aggregation Inhibitors
  • Polydeoxyribonucleotides
  • defibrotide
  • Gemtuzumab